Fresh analysis indicates that people who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle programs.
Published data in a major medical journal points out that while overweight individuals frequently drop a large proportion of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"Users using these treatments must be cognizant of the potential of rapid rebound weight gain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to starting weight in about 18 months.
Analyzing Treatments
The analysis, which examined 37 of studies involving over 9,000 of participants, contrasted the results of the injectable medications with older methods.
Researchers emphasize that people who shed pounds through diet and exercise typically have a slower weight regain—perhaps 100 grams monthly—once they finish.
Explaining the Quick Rebound
Doctors suggest the mode of action of the jabs explains the heightened weight return.
The injections mimic a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 concentrations far above than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication leads to appetite is unsuppressed, making overeating much more probable."
An Ongoing Condition?
The NHS recommend the injections for people with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians contend that, given the significant potential of weight regain, the treatment is often ongoing.
This opinion is echoed by drug manufacturers, who state that the results "emphasize the long-term nature of obesity," similar to managing diseases like high blood pressure.
User Accounts
Individuals who have come off the medication report a intense return of cravings.
"I experienced a switch that goes on and you're instantly ravenous," recalled a patient.
This challenge is worsened if patients have not adopted lasting dietary or behavioural changes during therapy.
Significant Adoption
Figures suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Use is higher among females than males.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone solution and long-term success likely depends on integrated lifestyle management.
